Selected article for: "post symptom and viral replication"
Author: Li, Haibo; Ren, Lili; Zhang, Lulu; Wang, Yeming; Guo, Li; Wang, Conghui; Xiao, Yan; Wang, Ying; Rao, Jian; Wang, Xinming; Liu, Ying; Huang, Chaolin; Gu, Xiaoying; Fan, Guohui; Li, Hui; Lu, Binghuai; Cao, Bin; Wang, Jianwei
Title: High anal swab viral load predisposes adverse clinical outcomes in severe COVID-19 patients
  • Cord-id: a7nj8sgl
  • Document date: 2020_12_24
    • ID: a7nj8sgl
    Snippet: To identify the association between the kinetics of viral load and clinical outcome in severe coronavirus disease 2019 (COVID-19) patients, a retrospective study was performed by involved 188 hospitalized severe COVID-19 patients in the LOTUS China trial. Among the collected 578 paired throat swab (TS) and anal swab (AS) samples, viral RNA was detected in 193 (33.4%) TS and 121 (20.9%) AS. A higher viral RNA load was found in TS than that of AS, with means of 1.0 × 10(6) and 2.3 × 10(5) copies
    Document: To identify the association between the kinetics of viral load and clinical outcome in severe coronavirus disease 2019 (COVID-19) patients, a retrospective study was performed by involved 188 hospitalized severe COVID-19 patients in the LOTUS China trial. Among the collected 578 paired throat swab (TS) and anal swab (AS) samples, viral RNA was detected in 193 (33.4%) TS and 121 (20.9%) AS. A higher viral RNA load was found in TS than that of AS, with means of 1.0 × 10(6) and 2.3 × 10(5) copies/ml, respectively. In non-survivors, the viral RNA in AS was detected earlier than that in survivors (median of 14 days vs 19 days, P = 0.007). The positivity and viral load in AS were higher in non-survivors than that of survivors at week 2 post symptom onset (P = 0.006). A high initial viral load in AS was associated with death (OR 1.368, 95% CI 1.076–1.741, P = 0.011), admission to the intensive care unit (OR 1.237, 95% CI 1.001–1.528, P = 0.049) and need for invasive mechanical ventilation (OR 1.340, 95% CI 1.076–1.669, P = 0.009). Our findings indicated viral replication in extrapulmonary sites should be monitored intensively during antiviral therapy.

    Search related documents:
    Co phrase search for related documents
    • absence presence and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and logistic regression model: 1, 2, 3, 4, 5, 6, 7
    • absence presence and logistic regression model analysis: 1
    • absence presence and long duration: 1, 2
    • absence presence and lopinavir ritonavir: 1, 2
    • absence presence and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • absence presence and lung disease severity: 1
    • absence presence and lysis buffer: 1, 2, 3, 4, 5
    • active virus replication and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • active virus replication and lung disease: 1
    • active virus replication proof and acute respiratory syndrome: 1
    • actively replicate and acute respiratory syndrome: 1, 2, 3
    • acute respiratory syndrome and logistic regression model analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir treat: 1, 2, 3, 4, 5
    • acute respiratory syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung disease severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lysis buffer: 1, 2, 3